A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 468 participants.

Also called NCT01986855

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 468 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01986855
  • EudraCT 2013-003587-31
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01986855. Randomized; double masking; primary purpose treatment. Start 2013-12-02 (actual); primary completion 2016-09-28 (actual). Results posted on 2017-10-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Ertugliflozin 5 mg
Intervention (Drug)
Placebo 5 mg
Intervention (Drug)
Ertugliflozin 10 mg
Intervention (Drug)
Placebo 10 mg
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)
Collaborator
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01986855
Content hash
c656bb396bfbc759af1d999759f9e1abf112cfd53e33ca25439a8ab594f63b51